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of inflammatory signaling by prostaglandin %sSo2 @ 
H, synthases 
Many nonsteroidal anti-inflammatory drugs act by inhibiting the cyclooxygenase 
activity of prostaglandin H, synthase (PGHS), a key enzyme in the biosynthesis 
of prostaglandins. Gastric toxicity remains a serious problem with the current 
drugs, however. Recent advances in the understanding of PGHS now suggest 
two possible approaches to producing drugs with fewer side effects. 
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Since the discovery in 1971 that aspirin and other non- nervous system modulates fever, pain and sleep functions. 
steroidal anti-inflammatory drugs (NSAIDs) block On the other hand, prostaglandins have functions unre- 
prostaglandin synthesis [ 11, inhibition of this pathway has lated to inflammation in kidney, bone and reproductive 
dominated NSAID research (see [2] for an excellent tissues. It is very likely that prostaglandins have a protec- 
review). Many well known NSAIDs, including ibuprofen, tive function in the gut, since stomach ulceration is a 
naproxen and indomethacin, potently inhibit the enzyme common side effect of PGHSl inhibition by NSAIDs. 
prostaglandin H, synthase-1 (PGHSl), which catalyzes the Through the efforts of several groups [3-71, the cDNAs 
first two committed steps in the formation of of PGHSl and a second isoform, PGHS2, were cloned 
prostaglandins, thromboxanes and prostacyclin. These in the late eighties and early nineties. Studies of their 
prostanoids serve as autocrine or paracrine hormones, sig- expression quickly provided convincing evidence of a 
naling a variety of cellular responses such as vasodilation, clear division of labor between the two isoforms. 
smooth muscle contraction and platelet aggregation via Although PGHSl is constitutively expressed in most cell 
cell surface receptors of the seven-transmembrane types, PGHS2 expression is usually low or undetectable. 
G-protein-coupled superfamily. Many proinflammatory ligands induce the rapid trans- 
cription and translation of PGHS2, resulting in a dra- 
As might be expected from the fact that PGHSl matic increase in prostaglandin production [5-71. In this 
inhibitors have anti-inflammatory effects, prostaglandins article, we examine recent attempts to obtain selective 
initiate inflammatory responses in peripheral tissues, inhibitors of PGHS2, and discuss an alternative mecha- 
inducing redness, edema, pain and heat sensations.There nism of inflammatory signaling by PGHS which may 
are also indications that prostaglandin synthesis in the offer additional targets for drug discovery 
Fig. 1. The PGHSl cyclooxygenase and 
peroxidase activities are found in distinct 
parts of the enzyme. The cyclooxygen- 
ase site, where arachidonic acid (AA) is 
oxidized to PGG, (reaction A), is 
hydrophobic, and buried within a 
channel that extends inward from the 
lipid bilayer. A tyrosine residue at posi- 
tion 385 separates the channel from the 
heme in the peroxidase active site. The 
peroxidase activity resides within a 
broad cleft on the surface of the protein, 
and is solvent-accessible. PGG, and 
other lipid peroxides are reduced here 
(reaction B), producing radical species. It 
is not known whether transfer between 
the cyclooxygenase and peroxidase 
active sites is passive or facilitated. 
PGG, 
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Structure of PGHSI 
The PGHS enzymes carry out two distinct catalytic steps 
(Fig. 1). In the first, arachidonic acid is &s-oxygenated to 
form the short-lived cyclic lipid hydroperoxide, PGG,. 
The activity responsible for this step in PGHSl is referred 
to as PGHSl cyclooxygenase. In the second step, the 
hydroperoxide group is reduced to an alcohol by PGHSl 
peroxidase, yielding the more stable PGH,. The recent 
elucidation of the crystallographic structure of ovine 
PGHSl [8] has yielded unexpected insights into the 
interrelationship of these activities, as well as providing 
invaluable information for drug design. 
PGHSl is structurally similar to myeloperoxidase, a 
secreted enzyme with microbicidal functions. Like other 
members of this conserved gene family, PGHSl displays 
peroxidase activity, has an essential heme cofactor, and 
releases free radicals. Unlike myeloperoxidase, however, 
PGHSl is localized to the endoplasmic reticulum and 
nuclear envelope. PGHSl is inserted into a single leaf of 
the lipid bilayer, facing the lumen, as a homodimer of 
70 kD subunits (Fig. 1). The PGHSl peroxidase active 
site lies within a broad cleft on the exterior surface of 
the protein, which is freely accessible to solvent and also 
contains the heme cofactor. In contrast, the cyclooxy- 
genase active site is found in the interior of the protein, 
at the apex of a hydrophobic channel which extends 
inward from the membrane bilayer. A tyrosine residue, 
Tyr385, is also found at the apex of the channel, separat- 
ing the hydrophobic channel from the heme prosthetic 
group in the peroxidase cleft on the surface of the 
protein. This tyrosine participates in a radical-mediated 
activation of the arachidonic acid substrate [9]. The 
hydrophobic channel contains the binding sites for com- 
petitive inhibitors of PGHSl such as flurbiprofen, and it 
is now clear that the irreversible inhibition of PGHSl by 
aspirin acetylation of Ser530 results from steric hin- 
drance of substrate access to the channel [lO].There have 
been no reports yet of inhibitors designed using infor- 
mation from the crystallographic structure, of PGHSl, 
but such inhibitors may be expected soon. 
Prostaglandin synthesis during proinflammatory signaling 
Prostaglandin production can be induced by inflamma- 
tory peptides, growth factors, cytokines or tumor pro- 
moters. Cell injury caused by ultraviolet radiation or 
ischemia-reperfusion also results in prostaglandin release. 
The released prostaglandins must be synthesized de novo, 
as no intracellular storage of prostaglandins has been 
observed. Before the PGHS enzymes can synthesize 
prostaglandins, arachidonic acid or other polyunsaturated 
fatty acids must be liberated from cellular phospholipids 
by the action of phospholipase A,, C or D (Fig. 2).The 
activation of phospholipases is tightly regulated by intra- 
cellular signaling pathways which are normally initiated 
by ligand binding to cell-surface receptors. Once arachi- 
donic acid has been released, PGHSl or PGHS2 can use 
it to synthesize PGH,. Subsequently, other enzymes 
further metabolize PGH, into various prostanoids spe- 
cific to each cell type. Some of the inflammatory effects 
of these compounds are shown in Figure 2. 
Several lines of evidence have indicated that PGHS2 
mediates the production of prostaglandins in inflamma- 
tory responses. First, PGHS2 expression is strongly 
induced by proinflammatory stimuli in vitro and in vivo, 
unlike PGHSl [5-7,11,12]; second, expression of 
PGHS2 can be attenuated by anti-inflammatory steroids 
(the corticosteroids), and this attenuation is paralleled by 
a reduction in inducible prostaglandin synthesis [6,13]. 
Fig. 2. Prostaglandin biosynthesis and 
inflammatory effects. Phospholipase A, 
directly releases arachidonic acid from 
phospholipids, but for the phospholi- 
pase C and D pathways di- and mono- 
acylglyceride lipases are also required. 
Once arachidonic acid has been 
released, one of the PCHS isoforms 
converts it to PCH,. The subsequent 
conversion of PGH, to prostaglandins, 
prostacyclin or thromboxanes depends 
on the cell-specific expression of appro- 
priate enzymes. The inflammatory 
responses to the products of these 
enzymes vary in different tissues. 
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Third, both PGHS2 protein synthesis and inducible 
prostaglandin production can be abolished by cyclohex- 
imide [13]; and, finally, an antisense PGHSZ oligo- 
nucleotide blocks expression of both PGHS2 and 
ligand-inducible prostaglandin synthesis [14]. 
PCHSZ-selective inhibitors: a second generation of NSAlDs 
The finding that indomethacin, a reversible cyclooxy- 
genase inhibitor, is a potent anti-inflammatory drug 
sparked a flurry of efforts to make similar inhibitors. In 
the late seventies and early eighties, powerful compounds 
such as naproxen, diclofenac and piroxicam were synthe- 
sized and characterized. These compounds effectively 
controlled the edema and pain associated with inflamma- 
tion, but the beneficial effects carried a price. 
Prostaglandins have an essential cytoprotective function 
in the stomach and intestine. Consequently, stomach 
ulceration seemed to be an unavoidable side effect of 
cyclooxygenase inhibition, and when few ideas emerged 
on how to separate toxicity from e@icacy the search for 
new NSAIDs waned. 
With the discovery of the inflammation-related PGHS2 
in 1991, however, hope quickly revived that PGHS2- 
selective cyclooxygenase inhibitors might have fewer side 
effects. Although the existing inhibitors showed little dis- 
crimination between the PGHS isoforms, several phar- 
maceutical companies rapidly identified a number of 
selective PGHS2 inhibitors by revisiting old compound 
libraries. Ivl viva studies [11,12,15,16] showed that 
PGHS2 inhibitors have potent anti-inflammatory activ- 
ity with little gastric toxicity, quite unlike their non- 
selective predecessors. Although there is as yet no proof 
that the improved gastric profile of these compounds 
directly results from the sparing of PGHSl cyclooxy- 
genase, PGHSl is the major isoform detected in the 
stomach (Fig. 3). Table 1 summarizes the inhibition of 
PGHSl and PGHS2 by selected compounds, along with 
some relevant biological observations. Three classes of 
inhibitors can be distinguished from these data, based on 
the mechanism of suppression: 
1) Reversible non-selective inhibitors of PGHSl and 
PGHS2. Most compounds in this category are competitive 
substrate inhibitors, including many pre-1990 NSAIDs. 
2) Selective PGHS2 inhibitors. These compounds are 
time-dependent, irreversible inhibitors of PGHS2, but 
reversibly inhibit PGHS 1 at high concentrations [17-l 91. 
3) Covalent inhibitors of PGHSl and PGHS2. Aspirin is 
the best-studied example of this class. More recently, 
certain amino (carboxyalkyl)maleimides were shown to act 
via this mechanism [20], though the site of modification 
has not been conclusively identified. 
Will PGHS2-selective inhibitors be the NSAIDs of the 
future? The answer seems likely to be yes. However, 
several points should be considered before assuming that 
all currently used NSAIDs will be obsolete. First, 
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Fig. 3. Distribution of PGHSl and PCHS2 RNA in normal (blue) 
and arthritic (red) rat tissues (D.C.M., unpublished data). Total 
RNA from indicated rat tissues was used for RNase protection 
with radiolabeled, isoform-specific PGHSl (a) or PGHS2 (b) 
complementary RNA. RNA copy number was determined relative 
to standards, as quantitated by computer-assisted densitometry of 
several autoradiographic exposures. Tissues were obtained from 
control or adjuvant arthritic rats sacrificed 15 days after injection. 
PGHS2 is the predominant isoform in normal rat 
brain, where it shows a cell-specific expression pattern; 
furthermore, brain expression can be superinduced by 
non-inflammatory stimuli ([21,22]; Figs 3,4). Therefore, 
PGHS2 inhibitors which can pass the blood-brain 
barrier will have to be assessed for adverse neurological 
effects. Second, the idea that selective PGHS2 inhibitors 
will be as effective as the non-selective inhibitors used 
until now rest in part on the demonstration that 
PGHS2, but not PGHSl, is upregulated immediately 
after adjuvant injection [7]. However, a quantitative 
comparison performed lo-15 days after injection, when 
swelling is at its peak, shows that PGHSl levels also rise 
three- to four-fold (Fig. 3). Because of its high basal 
level, PGHSl expression still predominates in most 
inflamed tissues, particularly the spleen. Therefore it may 
be too early to discount the possibility that PGHSl is 
important in inflammatory responses in at least some 
tissues. Third, PGHS2 has been implicated in non- 
inflammatory functions such as reproduction. PGHS2 
expression is seen in granulosa cells of ovulatory follicles 
[23,24], and preliminary results in mice suggest that 
homozygous PGHS2 gene knockout results in infertility 
346 Chemistry & Biology 1995, Vol 2 No 6 
3 
Sulindac sulfide 100 100-l 000 l-10 
F CH3 
HOOC H Cl 
dub 
k 
Diclofenac 10 10 
Cl 
Table 1. Inhibition of PGHSl and PGHSZ cyclooxygenase activities by selected NSAlDs. 
IC,, values (nM) in PGHSl and PGHS2 whole cell assays= 
PGHSZ PGHSl PGHSl/PCHSl 
H3c+&;yOH 
lndomethacin 50 10 0.2 
0’ 
0 
1: 
Flurbiprofen 1 
HO0 
HOOC ‘: I 
e5& 
CH3 
Cl 
Meclofenamic acidb l-10 lo-100 10 
HOOCF Ibuprofen 1000 10000 10 
y CO$\rfH 
Q 
\ n Flosulide 50 >50 000 >lOOO 
F F 
0 
8 
H3C02S- \ 
a 
NS-398C 1 >lO 000 >lO 000 
/ 
NO2 
Y Co2hdH 
Q 
3 pF 
L-745 337 50 >lO 000 >200 
‘Reproduced from [32]. 
‘Time-dependent inhibitor for both PGHSl and PGHS2. 
Time-dependent inhibitor for PGHSZ but not PGHSl. 
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Table 1 (continued). 
DuP 697e 7 38.5 5.5 
X6882 
X6140 
SC581 25 
IC,, values (FM) in ovine PGHSl and human PGHSZ assaysd 
PGHSZ PGHSl 
(human) (ovine) 
PGHSl/PGHSZ 
198 
7.8 
>300 
493 
1.5 
63.2 
IC,, values (FM) from PGHSl and PCHSZ assays expressed in baculovirusf 
PCHSZ PCHSl PGHSl/PGHSZ 
0.05 >lO >200 
dReproduced from [33]. 
eTme-dependent inhibitor for PCHSZ but not PCHSl. 
fSee [61. 
(H. Herschman & D.L. Dewitt, personal communica- 
tion). Thus, careful evaluation will be necessary before 
PGHS2 inhibitors can be declared the winners in the 
NSAIDs sweepstakes. 
PCHS peroxidase: a third prong in the NSAID assault? 
Although a highly selective PGHS2 inhibitor may well 
be important in the development of NSAIDs with 
reduced gastrointestinal toxicity, recent data suggest that 
another approach is worth exploring. This approach was 
suggested by the fact that tepoxalin, a compound origi- 
nally identified as a dual PGHS and 5-lipoxygenase 
inhibitor, shows potent anti-inflammatory effects 
without gastric toxicity in rat adjuvant arthritis [25]. The 
lack of gastric lesions cannot be explained by 5-lipoxy- 
genase inhibition, since pretreatment with tepoxalin did 
not significantly reduce the damage induced by 
indomethacin. Intravital microscopy showed that tepox- 
alin did not cause leukocyte adherence to mesenteric 
venules, whereas other NSAIDs did (Anderson, D.W., et 
al., & Capetola, R.J. (1990). FASEB 1. 4, A1142, and 
[26]). Close examination of the differences suggested that 
tepoxalin might inhibit neutrophil migration into the 
pin-hole stomach lesions initially caused by cyclooxy- 
genase inhibition. Just such an effect was demonstrated in 
a mouse skin inflammation model, where tepoxalin 
effectively inhibited neutrophil infiltration and blocked 
upregulation of the adhesion molecules E-selectin and 
MAC-l (our unpublished data). 
The expression of adhesion molecules in inflammation 
(and also that of chemotactic factors and cytokines) is con- 
trolled by the inducible transcription factor NF-KB. The 
effect of tepoxalin on the expression of several NF-KB- 
dependent genes was therefore examined. Induction of E- 
selectin, MAC-1 andVCAM-1 in cultured leukocytes was 
suppressed by tepoxalin, and activation of NF-KB function 
was also inhibited ([27] and unpublished data). The drug 
also inhibited the upregulation of the NF-KB-dependent 
cytokines IL-2, IL-6, IL-8 and interferon-y [27,28]. In 
addition to its anti-inflammatory properties, tepoxalin 
showed immunosuppressive effects in cultured cells, 
348 Chemistry & Biology 1995, Vol 2 No 6 
Fig. 4. Cell-specific expression of PGHSZ 
mRNA in rat brain. In situ hybridization 
was carried out with a digoxigenin- 
labeled, isoform-specific PGHS2 com- 
plementary RNA (unpublished data 
kindly provided by Dr Lubing Zhou). (a) 
Sagittal section showing a high density of 
PGHSZ-positive hippocampal neurons. 
(b) Boxed area from (a) is shown at 
higher magnification. 
inhibiting T-cell proliferation induced by IL-2 or PMA 
plus ionophore, and synergizes with cyclosporin A in sup- 
pressing mouse skin allograft reject& [29]. 
How can tepoxalin’s actions be explained? NF-KB can be 
activated by many of the same stimuli that provoke 
prostaglandin synthesis, apparently using intracellular 
reactive oxygen intermediates (ROI) as a common second 
messenger [30]. We have found that PGHSl can partici- 
pate in activation of NF-KB by ROI (our unpublished 
data). Expression of the enzyme in COS cells dramatically 
enhanced NF-KB activation by PMA, as well as produc- 
tion of ROI. Both functions required intact peroxidase 
activity, but not cyclooxygenase activity, as shown by site- 
directed mutagenesis and NSAID inhibition. Therefore, 
we propose that PGHSl may be important in activating 
NF-t&dependent gene expression during inflammation. 
The idea that PGHSl peroxidase could signal to 
NF-KB via ROIs makes sense in the light of what is 
already known about the enzyme. PGHSl peroxidase 
can reduce peroxides produced by superoxide dismu- 
tase or lipoxygenases, as well as by cyclooxygenase, and 
produces two radicals for each peroxide reduced. Using 
purified PGHSl, we found that tepoxalin but not 
naproxen or indomethacin inhibited PGHSl peroxi- 
dase [31]. Certain analogs of tepoxalin that had previ- 
ously been shown to inhibit NF-KB activation were 
also the most potent inhibitors of PGHSl peroxidase 
activity. Structure-activity studies demonstrated that 
tepoxalin has two functionalities (Fig. 5). The substi- 
tuted pyrazole inhibits PGHSl cyclooxygenase, 
whether or not the hydroxamic acid group is present. 
The hydroxamic acid moiety, however, adds a peroxi- 
dase inhibitory functionality to the pyrazole structure, 
probably by interacting with the hemic iron. Thus, 
it seems likely that tepoxalin’s novel mechanism of 
action stems from inhibition of PGHSl peroxidase and 
subsequent suppression of NF-KB activation during 
inflammatory challenges. 
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Fig. 5. The structural motifs associated with PGHSl cyclooxy- 
genase and peroxidase inhibition by tepoxalin. (a) The bis-substi- 
tuted pyrazole group is required for high-affinity binding to 
PGHSl and cyclooxygenase inhibition, associated with typical 
NSAID effects. (b) The hydroxamic acid group interacts with 
enzyme-bound heme, inhibiting free-radical release by PGHSl 
peroxidase, and thereby blocking subsequent NF-KB activation. 
Conclusions 
The isolation of the PGHS2 isoform and the identifica- 
tion of PGHS peroxidase as an important contributor to 
NF-KB activation clearly open new avenues to the dis- 
covery of novel NSAIDs. Selective inhibitors of either 
PGHSl or PGHS2 and dual inhibitors of PGHSI 
cyclooxygenase and peroxidase are available. Interestingly, 
adding a hydroxamic acid arm to naproxen resulted in a 
dual cyclooxygenase/peroxidase inhibitor which inhib- 
ited NF-KB activation, like tepoxalin (our unpublished 
data). This may provide a general strategy for the design 
of other dual inhibitors based on known cyclooxygenase 
inhibitors, including those which show selectivity for 
PGHS2. In-depth investigation of these compounds in 
viuo will be necessary before we achieve the ultimate goal 
of a safe and potent NSAID without gastric toxicity. 
However, the current generation of NSAIDs provide 
new tools to dissect the processes controlling inflamma- 
tion. Equally important, they point the way to future 
anti-inflammatory compounds with great therapeutic 
and economic potential. 
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